| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.
|
Blood
|
2010
|
4.51
|
|
2
|
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome.
|
Cancer
|
2006
|
4.04
|
|
3
|
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.
|
J Clin Oncol
|
2012
|
3.88
|
|
4
|
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
|
Blood
|
2007
|
3.27
|
|
5
|
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.
|
Blood
|
2003
|
3.18
|
|
6
|
Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
|
Cancer
|
2004
|
2.78
|
|
7
|
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.
|
J Clin Oncol
|
2008
|
2.54
|
|
8
|
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
|
Blood
|
2012
|
2.32
|
|
9
|
Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
|
Blood
|
2006
|
2.31
|
|
10
|
DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes.
|
J Clin Oncol
|
2009
|
2.23
|
|
11
|
The incidence and impact of thrombocytopenia in myelodysplastic syndromes.
|
Cancer
|
2007
|
2.21
|
|
12
|
Cause of death in patients with lower-risk myelodysplastic syndrome.
|
Cancer
|
2010
|
2.17
|
|
13
|
Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia.
|
Cancer
|
2008
|
2.07
|
|
14
|
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.
|
J Clin Oncol
|
2010
|
2.02
|
|
15
|
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.
|
Br J Haematol
|
2007
|
1.85
|
|
16
|
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.
|
J Clin Oncol
|
2009
|
1.83
|
|
17
|
Late relapses in acute myeloid leukemia: analysis of characteristics and outcome.
|
Leuk Lymphoma
|
2010
|
1.73
|
|
18
|
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.
|
Blood
|
2013
|
1.70
|
|
19
|
Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia.
|
Blood
|
2003
|
1.65
|
|
20
|
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities.
|
Blood
|
2013
|
1.64
|
|
21
|
Modest activity of pomalidomide in patients with myelofibrosis and significant anemia.
|
Leuk Res
|
2013
|
1.61
|
|
22
|
Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia.
|
Leuk Lymphoma
|
2014
|
1.59
|
|
23
|
Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model.
|
J Clin Oncol
|
2011
|
1.55
|
|
24
|
Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy.
|
Blood
|
2010
|
1.50
|
|
25
|
Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.
|
Blood
|
2004
|
1.49
|
|
26
|
JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms.
|
Blood
|
2013
|
1.46
|
|
27
|
The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia.
|
Cancer
|
2011
|
1.42
|
|
28
|
Outcome of adults with acute lymphocytic leukemia after second salvage therapy.
|
Cancer
|
2008
|
1.40
|
|
29
|
Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor.
|
Leuk Lymphoma
|
2014
|
1.40
|
|
30
|
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.
|
Blood
|
2012
|
1.39
|
|
31
|
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
|
Cancer
|
2006
|
1.36
|
|
32
|
Biphenotypic acute leukaemia: a case series.
|
Br J Haematol
|
2007
|
1.36
|
|
33
|
Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities.
|
Cancer
|
2009
|
1.29
|
|
34
|
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.
|
Blood
|
2008
|
1.25
|
|
35
|
Cytogenetic profile of patients with acute myeloid leukemia and central nervous system disease.
|
Cancer
|
2011
|
1.21
|
|
36
|
Thalidomide therapy for myelofibrosis with myeloid metaplasia.
|
Cancer
|
2006
|
1.18
|
|
37
|
PML-RARalpha is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival.
|
Blood
|
2003
|
1.17
|
|
38
|
Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse.
|
Leuk Res
|
2009
|
1.16
|
|
39
|
The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients.
|
Clin Cancer Res
|
2008
|
1.16
|
|
40
|
CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia.
|
Leuk Res
|
2002
|
1.15
|
|
41
|
Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia.
|
Biol Blood Marrow Transplant
|
2009
|
1.14
|
|
42
|
Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia.
|
Blood
|
2007
|
1.14
|
|
43
|
The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course.
|
Blood
|
2009
|
1.11
|
|
44
|
Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia.
|
Blood
|
2011
|
1.11
|
|
45
|
Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience.
|
Int J Hematol
|
2009
|
1.11
|
|
46
|
Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers.
|
Blood
|
2011
|
1.10
|
|
47
|
Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration.
|
Cancer
|
2010
|
1.09
|
|
48
|
EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience.
|
Blood
|
2012
|
1.08
|
|
49
|
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
|
Cancer
|
2014
|
1.08
|
|
50
|
Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia.
|
Br J Haematol
|
2011
|
1.07
|
|
51
|
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.
|
Blood
|
2005
|
1.06
|
|
52
|
Impact of age on outcome of pediatric acute myeloid leukemia: a report from 2 institutions.
|
Cancer
|
2006
|
1.05
|
|
53
|
Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
|
J Clin Oncol
|
2009
|
1.02
|
|
54
|
Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin.
|
Cancer
|
2011
|
1.02
|
|
55
|
Outcome of patients with acute myelogenous leukemia after second salvage therapy.
|
Cancer
|
2005
|
1.01
|
|
56
|
Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia.
|
J Clin Oncol
|
2008
|
1.00
|
|
57
|
Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia.
|
Cancer
|
2009
|
0.99
|
|
58
|
Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation.
|
J Clin Oncol
|
2011
|
0.97
|
|
59
|
Comparison of thalidomide and lenalidomide as therapy for myelofibrosis.
|
Blood
|
2011
|
0.97
|
|
60
|
The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes.
|
Cancer
|
2008
|
0.96
|
|
61
|
Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment.
|
Cancer Biol Ther
|
2012
|
0.96
|
|
62
|
Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia.
|
Am J Hematol
|
2013
|
0.96
|
|
63
|
Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy.
|
Cancer
|
2010
|
0.96
|
|
64
|
Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.
|
Cancer
|
2008
|
0.95
|
|
65
|
Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia.
|
Cancer
|
2008
|
0.94
|
|
66
|
Myelodysplastic syndrome is not merely "preleukemia".
|
Blood
|
2002
|
0.94
|
|
67
|
Significance of cytogenetic abnormalities in patients with polycythemia vera.
|
Leuk Lymphoma
|
2013
|
0.93
|
|
68
|
Protein expression of a triad of frequently methylated genes, p73, p57Kip2, and p15, has prognostic value in adult acute lymphocytic leukemia independently of its methylation status.
|
J Clin Oncol
|
2005
|
0.93
|
|
69
|
Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.92
|
|
70
|
Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia.
|
Leuk Res
|
2008
|
0.91
|
|
71
|
Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia.
|
Haematologica
|
2012
|
0.91
|
|
72
|
Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD.
|
Br J Haematol
|
2013
|
0.91
|
|
73
|
Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia.
|
Cancer
|
2009
|
0.91
|
|
74
|
Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome.
|
Support Care Cancer
|
2009
|
0.90
|
|
75
|
Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia.
|
Clin Lymphoma Myeloma Leuk
|
2011
|
0.89
|
|
76
|
Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.
|
Cancer
|
2009
|
0.89
|
|
77
|
Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents.
|
Leuk Lymphoma
|
2014
|
0.89
|
|
78
|
Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes.
|
Am J Hematol
|
2014
|
0.89
|
|
79
|
Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS.
|
Cancer
|
2012
|
0.87
|
|
80
|
Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies.
|
Leuk Res
|
2004
|
0.86
|
|
81
|
Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody.
|
Am J Hematol
|
2015
|
0.86
|
|
82
|
Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy.
|
Cancer
|
2004
|
0.86
|
|
83
|
The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia.
|
Front Oncol
|
2013
|
0.85
|
|
84
|
Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study.
|
Cancer
|
2010
|
0.85
|
|
85
|
Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.85
|
|
86
|
Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy.
|
Cancer
|
2009
|
0.85
|
|
87
|
Aberrant DNA methylation of a cell cycle regulatory pathway composed of P73, P15 and P57KIP2 is a rare event in children with acute lymphocytic leukemia.
|
Leuk Res
|
2005
|
0.85
|
|
88
|
Overexpression of the toll-like receptor (TLR) signaling adaptor MYD88, but lack of genetic mutation, in myelodysplastic syndromes.
|
PLoS One
|
2013
|
0.85
|
|
89
|
Prognostic impact of RAS mutations in patients with myelodysplastic syndrome.
|
Am J Hematol
|
2013
|
0.85
|
|
90
|
Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen.
|
Cancer
|
2010
|
0.84
|
|
91
|
Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome.
|
Br J Haematol
|
2012
|
0.83
|
|
92
|
The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?
|
Cancer
|
2009
|
0.83
|
|
93
|
Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission.
|
Leuk Lymphoma
|
2010
|
0.83
|
|
94
|
Chromosome 5q deletion is extremely rare in patients with myelofibrosis.
|
Leuk Res
|
2013
|
0.83
|
|
95
|
Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse.
|
Leuk Lymphoma
|
2013
|
0.83
|
|
96
|
Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia.
|
Haematologica
|
2012
|
0.83
|
|
97
|
Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia.
|
Blood
|
2013
|
0.82
|
|
98
|
Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.82
|
|
99
|
Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction.
|
Cancer
|
2010
|
0.82
|
|
100
|
Comorbidities predict worse prognosis in patients with primary myelofibrosis.
|
Cancer
|
2014
|
0.81
|
|
101
|
Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months.
|
Haematologica
|
2013
|
0.81
|
|
102
|
Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.
|
J Clin Oncol
|
2009
|
0.81
|
|
103
|
Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience.
|
Am J Hematol
|
2014
|
0.80
|
|
104
|
Feasibility of therapy with hypomethylating agents in patients with renal insufficiency.
|
Clin Lymphoma Myeloma Leuk
|
2010
|
0.80
|
|
105
|
TP53 mutation is rare in primary myelofibrosis.
|
Leuk Lymphoma
|
2012
|
0.80
|
|
106
|
Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome.
|
Am J Hematol
|
2011
|
0.80
|
|
107
|
Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.80
|
|
108
|
Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias.
|
Genes Chromosomes Cancer
|
2010
|
0.80
|
|
109
|
Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide.
|
Leuk Lymphoma
|
2014
|
0.80
|
|
110
|
Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications.
|
Clin Lymphoma Myeloma Leuk
|
2011
|
0.79
|
|
111
|
Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome.
|
Cancer
|
2010
|
0.79
|
|
112
|
Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system.
|
Cancer
|
2012
|
0.79
|
|
113
|
Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis.
|
Br J Haematol
|
2014
|
0.79
|
|
114
|
Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia.
|
Am J Hematol
|
2014
|
0.79
|
|
115
|
Characteristics of pericardial effusions in patients with leukemia.
|
Cancer
|
2010
|
0.78
|
|
116
|
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.
|
Cancer
|
2006
|
0.78
|
|
117
|
Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia.
|
Blood
|
2008
|
0.78
|
|
118
|
Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation.
|
Int J Hematol
|
2009
|
0.78
|
|
119
|
Prediction model for mortality after intracranial hemorrhage in patients with leukemia.
|
Am J Hematol
|
2011
|
0.77
|
|
120
|
Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia.
|
Cancer
|
2012
|
0.77
|
|
121
|
Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study.
|
Am J Hematol
|
2013
|
0.77
|
|
122
|
The effect of calcium channel blockers on the outcome of acute myeloid leukemia.
|
Leuk Lymphoma
|
2014
|
0.77
|
|
123
|
Clinical and cytogenetic characteristics of myelodysplastic syndrome in patients with HIV infection.
|
Leuk Res
|
2012
|
0.76
|
|
124
|
Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome.
|
Leuk Res
|
2013
|
0.75
|
|
125
|
Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia.
|
Am J Hematol
|
2012
|
0.75
|
|
126
|
Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.75
|